Drug insight: Use of docetaxel in prostate and urothelial cancers.
about
3D Cultures of prostate cancer cells cultured in a novel high-throughput culture platform are more resistant to chemotherapeutics compared to cells cultured in monolayerThe Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.BMI1 polycomb group protein acts as a master switch for growth and death of tumor cells: regulates TCF4-transcriptional factor-induced BCL2 signaling.BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer.miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivoDual Drug Loaded Biodegradable Nanofibrous Microsphere for Improving Anti-Colon Cancer Activity.The chemomodulatory effects of glufosfamide on docetaxel cytotoxicity in prostate cancer cells.Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism.Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer.Enhancing cytotoxic therapies for breast and prostate cancers with polyunsaturated fatty acids.Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancerLenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21.CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.Combination effects of docetaxel and Doxorubicin in hormone-refractory prostate cancer cells.Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer.The use of nanoparticulates to treat breast cancer.Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells.
P2860
Q28544801-FA84A0E2-B288-4D2C-A8F1-DBECAFCAE85EQ33702987-A8E2057F-9447-4E2A-BAB1-98AF29BE4B57Q33959529-5D073A5F-2EDF-43E5-8202-FD8CB2E8DD48Q34720367-C5EF4481-0F8E-4103-99BA-F459BA99B766Q35691501-3CE87B3F-0F77-4B4D-8F02-96C01D31F7A0Q36610611-CA344FB7-5BB3-428D-99E6-AB27DF93703CQ37023985-26976D78-8B0C-44A5-BC3C-249C7E1F9A1AQ37065525-4003DC6D-8495-4EB8-A806-A288DDAC271FQ37463153-344EB5E9-5B13-4550-BB72-1A694A9C7239Q37718444-600DCEF2-590F-4F30-84D0-87183774BC08Q37722636-C482201B-F730-4F0B-A656-3C4E095288CFQ39042632-9BD7BA31-F8ED-4EA1-A6E8-2CEEA62773A9Q39463711-821E1FFF-7DD9-4D5A-9315-1A6491F153B9Q39715241-90BDB355-6D2F-40B5-8DC4-6C2E62355A47Q39782144-D870893B-275D-4080-93FE-F554F41A40F2Q41853267-C3FF691B-C16F-4E6B-8340-7867FBE4F943Q43875491-6991A872-E131-45E5-A8E1-274E7FD514C5Q45066468-B6061091-76EB-43FE-93F3-527F9451A788Q48371276-8D62892E-45F4-451F-A7D7-36CA36696968
P2860
Drug insight: Use of docetaxel in prostate and urothelial cancers.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Drug insight: Use of docetaxel in prostate and urothelial cancers.
@ast
Drug insight: Use of docetaxel in prostate and urothelial cancers.
@en
type
label
Drug insight: Use of docetaxel in prostate and urothelial cancers.
@ast
Drug insight: Use of docetaxel in prostate and urothelial cancers.
@en
prefLabel
Drug insight: Use of docetaxel in prostate and urothelial cancers.
@ast
Drug insight: Use of docetaxel in prostate and urothelial cancers.
@en
P2860
P356
P1476
Drug insight: Use of docetaxel in prostate and urothelial cancers.
@en
P2093
Kenneth J Pienta
Niklas J Mackler
P2860
P2888
P304
92-100; quiz 1 p following 112
P356
10.1038/NCPURO0099
P407
P577
2005-02-01T00:00:00Z